Exactly ten years ago today, on January 29, 2014, I wrote about two new Nature papers on so-called STAP cells. The papers claimed that stress alone could convert regular non-stem cells into some of the most powerful stem cells. More specifically, the authors claimed to make pluripotent stem cells similar to iPS cells this way. …
I’m trying to remember the first time I ever heard about clones. It had to be as a kid. Maybe in a monster movie or TV show? Possibly a clone was referred to by the more general term “double”, which is not necessarily a clone. Whatever it was, I’m sure as a kid that I …
Weekly reads: game of clones, super-SOX, Moonwalk Bio, Great Wall’s living skin Read More »
Each year I make predictions for the stem cell and regenerative medicine field for the following year. Today’s prediction post is focused on what to expect in 2024. You can also see my stem cell predictions for 2023 and my grades on how I did. I also have made a video version of these predictions so please …
20 stem cell & regenerative medicine predictions for 2024 Read More »
For about as long as I’ve been writing The Niche, people have been asking about stem cells for MS. There’s a huge need for new therapies. While a chemo-based approach with autologous hematopoietic stem cell transplantation (HSCT) looks to work for certain cases of multiple sclerosis (although not yet approved in the US), other cell …
Weekly reads: stem cells for MS, good news x2, extending dog years, Neuralink updates Read More »
Some folks can view data from early, small clinical trials too skeptically or overly enthusiastically, and maybe that’s going on with some preliminary results from Verve Therapeutics. Good news? Bad news? I’m going to start with two articles about the same news that have very different vibes. What do I think? On the whole, I …
Weekly reads: Verve Therapeutics, Casgevy UK OK, GDNF, MYC Read More »
Paolo Macchiarini is one of a small group of people in the stem cell universe whose misconduct has blown up in the press. Piero Anversa, Haruko Obokata, Hwang Woo-Suk, and some operators in the unproven stem cell clinic sphere come to mind. Macchiarini published quite a few seriously problematic papers, some of which just hung …
Weekly reads: late Macchiarini retractions, stem cells & Lululemon Read More »
I’ve been more interested in histones and their modifications versus DNA methylation when it comes to epigenetics and chromatin. In part this has just been because I have studied histones so much more. For example, we have been knocking out the two histone variant H3.3 genes, H3f3a and H3f3b, now for a decade. My lab also …
Weekly reads: DNA methylation, H3 K27M in glioma, memory wipe, teeth Read More »
I’ve been thinking more about the steady stream of epigenetic clock research out there. How convincing is the research on such clocks? Do they tightly relate to human biological age? The related notion of turning back such hypothetical clocks to reverse aging is exciting but controversial. It doesn’t help that some are hyping all of …
Is DNA methylation destiny? Diving into new epigenetic clock research Read More »
Early during my postdoc I was primarily interested in the role of Myc genes both in cancer and in stem cells, work that later included embryonic stem cells. These cells are often called ES cells. At first I first started studying N-Myc in neural stem cells using a conditional knockout approach. However, soon after I was …
Weekly reads: embryonic stem cells, Parkinson’s, Alzheimer’s Read More »
Altos Labs is an intriguing multi-institution experiment in so-called rejuvenation research all rolled into one biotech. This relatively new entity headquartered in California has multiple Nobel laureates in the biomedical field in leadership. Even more importantly it has a large group of great researchers leading its individual research labs. This all leads to high expectations, …
Some surprises from new analysis of Altos Labs papers Read More »